Pdt Partners, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 16,241 shares of ARWR stock, worth $307,929. This represents 0.03% of its overall portfolio holdings.

Number of Shares

16,241

Holding current value

$307,929

% of portfolio

0.03%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $314,425 - $479,759	16,241 New	16,241 $314,000
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $189,365 - $308,749	6,391 New	6,391 $211,000
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $463,648 - $844,377	-16,684 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $459,473 - $811,442	11,597 Added 227.97%	16,684 $767,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $724,208 - $1.03 Million	-12,467 Reduced 71.02%	5,087 $337,000
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $507,906 - $739,152	8,700 Added 98.26%	17,554 $1.1 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $550,276 - $799,693	8,854 New	8,854 $733,000
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $234,174 - $456,217	-5,344 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$33.21 - $51.27 $177,474 - $273,986	5,344 New	5,344 $230,000
Q3 2018 Nov 14, 2018	SELL	$14.0 - $20.3 $1.46 Million - $2.12 Million	-104,500 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $2.26 Million - $4.98 Million	-354,900 Reduced 77.25%	104,500 $1.42 Million
Q1 2018 May 15, 2018	BUY	$3.72 - $7.64 $462,024 - $948,888	124,200 Added 37.05%	459,400 $3.31 Million
Q4 2017 Feb 14, 2018	BUY	$3.14 - $4.5 $1.05 Million - $1.51 Million	335,200	335,200 $1.23 Million

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account